Last updated on November 2018

Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease


Brief description of study

PRECISION-HD2 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of WVE-120102 in adult patients with early manifest Huntington's disease (HD) who carry a targeted single nucleotide polymorphism (SNP) rs362331 (SNP2).

Clinical Study Identifier: NCT03225846

Contact Investigators or Research Sites near you

Start Over

Mark Guttman, MD

Centre For Movement Disorders
Toronto, ON Canada
  Connect »

Grzegorz Witkowski, MD

Instytut Psychiatrii i Neurologii
Warsaw, Poland
  Connect »

Sylvain Chouinard, MD

Centre Hospitalier de l-Universite de Montreal
Montreal, QC Canada
  Connect »